Does naloxone provision lead to increased substance use? A systematic review to assess if there is evidence of a 'moral hazard' associated with naloxone supply
- PMID: 34798434
- DOI: 10.1016/j.drugpo.2021.103513
Does naloxone provision lead to increased substance use? A systematic review to assess if there is evidence of a 'moral hazard' associated with naloxone supply
Abstract
Background: Take home naloxone (THN) programs have been rapidly upscaled in response to increasing opioid-related mortality. One often cited concern is that naloxone provision could be associated with increased opioid use, due to the availability of naloxone to reverse opioid overdose. We conducted a systematic review to determine whether THN provision is associated with changes in substance use by participants enrolled in THN programs.
Methods: We conducted a systematic review of the literature to assess changes in heroin or other substance use by people who use opioids following THN provision.
Results: Seven studies with 2578 participants were included. Of the seven studies, there were two quasi-experimental studies and five cohort studies. Based on the Joanna Briggs Institute quality assessment, four studies were of moderate quality and three studies were of high quality. Of the five studies that reported on the primary outcome of heroin use, no study found evidence of increased heroin use across the study population. Five studies reported on other substance use (benzodiazepines, alcohol, cocaine, amphetamine, cannabis, prescription opioids), none of which found evidence of an increase in other substance use associated with THN provision. Four studies reported on changes in overdose frequency following THN provision: three studies reporting no change, and one study of people prescribed opioids finding a reduction in opioid-related emergency department attendances for participants who received naloxone.
Conclusion: We found no evidence that THN provision was associated with increased opioid use or overdose. Concerns that THN supply may lead to increased substance use were not supported by data from reviewed studies.
Keywords: Heroin; Moral hazard; Naloxone; Substance use; Take home naloxone.
Copyright © 2021 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declarations of Interest In the past 5 years, SN and SL have been investigators on untied education grants from Indivior, unrelated to the current work. SN has provided training to health care professionals on identifying and treating codeine dependence for which her institution has received payment from Indivior. SN and TL have been investigators on untied educational grants from Seqirus, unrelated to the current work. PD has received an investigator-driven grant from Gilead Sciences for unrelated work on Hepatitis C and an untied educational grant from Reckitt Benckiser for unrelated work on the introduction of buprenorphine-naloxone into Australia. PD and SN have served as unpaid members of an Advisory Board for an intranasal naloxone product.
Similar articles
-
Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.Cochrane Database Syst Rev. 2018 Jun 5;6(6):CD006332. doi: 10.1002/14651858.CD006332.pub3. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2022 Sep 15;9:CD006332. doi: 10.1002/14651858.CD006332.pub4. PMID: 29869799 Free PMC article. Updated.
-
Take-Home Naloxone in Opioid Dependency: An Intervention to Reduce Opioid-Related Deaths.Dtsch Arztebl Int. 2025 May 2;122(9):240-244. doi: 10.3238/arztebl.m2025.0030. Dtsch Arztebl Int. 2025. PMID: 40073286 Review.
-
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.Cochrane Database Syst Rev. 2022 Sep 5;9(9):CD011117. doi: 10.1002/14651858.CD011117.pub3. Cochrane Database Syst Rev. 2022. PMID: 36063082 Free PMC article.
-
Agent-Based Model of Combined Community- and Jail-Based Take-Home Naloxone Distribution.JAMA Netw Open. 2024 Dec 2;7(12):e2448732. doi: 10.1001/jamanetworkopen.2024.48732. JAMA Netw Open. 2024. PMID: 39656460 Free PMC article.
-
Implementation of Medication Disposal Programs and Availability of Same-Day Naloxone at Community Pharmacies: Protocol for a Secret Shopper Caller Approach.JMIR Res Protoc. 2025 Jun 10;14:e64344. doi: 10.2196/64344. JMIR Res Protoc. 2025. PMID: 40493386 Free PMC article.
Cited by
-
Evaluating the impact of naloxone dispensation at public health vending machines in Clark County, Nevada.Ann Med. 2022 Dec;54(1):2692-2700. doi: 10.1080/07853890.2022.2121418. Ann Med. 2022. PMID: 36168975 Free PMC article.
-
"There's absolutely no downside to this, I mean, except community opposition:" A qualitative study of the acceptability of vending machines for harm reduction.Harm Reduct J. 2023 Feb 28;20(1):25. doi: 10.1186/s12954-023-00747-4. Harm Reduct J. 2023. PMID: 36855064 Free PMC article.
-
Effectiveness of direct patient outreach with a narrative naloxone and overdose prevention video to patients prescribed long-term opioid therapy in the USA: the Naloxone Navigator randomised clinical trial.BMJ Public Health. 2024 Jul;2(1):e000725. doi: 10.1136/bmjph-2023-000725. Epub 2024 Jul 8. BMJ Public Health. 2024. PMID: 39421268 Free PMC article.
-
Expert views on state-level naloxone access laws: a qualitative analysis of an online modified-Delphi process.Harm Reduct J. 2022 Jun 8;19(1):64. doi: 10.1186/s12954-022-00645-1. Harm Reduct J. 2022. PMID: 35676719 Free PMC article.
-
Pharmacy naloxone codispensing: A mixed methods study of practices and perspectives under a statewide standing order program.J Am Pharm Assoc (2003). 2022 Sep-Oct;62(5):1546-1554. doi: 10.1016/j.japh.2022.03.015. Epub 2022 Mar 19. J Am Pharm Assoc (2003). 2022. PMID: 35450833 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical